Higher Steroid Exposure Linked to Systemic Adverse Events in CRSwNP - Report - MDSpire
Advertisement
Higher Steroid Exposure Linked to Systemic Adverse Events in CRSwNP
Higher annual oral corticosteroid exposure was associated with greater odds of systemic adverse events, with avascular bone necrosis and pneumonia showing dose-dependent associations with cumulative dose and osteoporosis associated with longer annual exposure duration.
Higher Steroid Exposure Linked to Systemic Adverse Events in CRSwNP
Overview
A nationwide nested case-control study found that higher annual oral corticosteroid exposure in patients with chronic rhinosinusitis with nasal polyps is associated with increased odds of systemic adverse events. The study analyzed data from 165,361 patients and highlighted significant risks related to cumulative corticosteroid doses and treatment duration.
Background
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent condition that often requires systemic corticosteroid treatment. This study provides insights into the relationship between corticosteroid exposure and systemic adverse events in a large patient population.
Data Highlights
Exposure Metric
Adjusted Odds Ratio
≥1.0 g/year vs <0.5 g/year
1.23
Duration >90 days/year vs ≤30 days/year
Higher odds of avascular bone necrosis, osteoporosis, pneumonia
Key Findings
Patients receiving ≥1.0 g of prednisolone-equivalent corticosteroids annually had 23% higher odds of any systemic adverse event.
Those with cumulative doses of ≥1.0 g/year had 2.6 times the odds of avascular bone necrosis compared to those receiving <0.5 g/year.
Patients treated for >90 days/year had increased odds of avascular bone necrosis, osteoporosis, and pneumonia.
High cumulative doses were linked to dyslipidemia, heart failure, hypertension, and type 2 diabetes, though clinical importance was uncertain.
Prescription frequency did not correlate with overall adverse-event risk but was associated with avascular bone necrosis.
Clinical Implications
Clinicians should be aware of the increased risk of systemic adverse events associated with higher doses and longer durations of oral corticosteroid therapy in patients with CRSwNP. Careful monitoring and consideration of alternative therapies may be warranted to mitigate these risks.
Conclusion
This study highlights the significant association between higher corticosteroid exposure and systemic adverse events in CRSwNP patients, emphasizing the need for cautious prescribing practices.
